Ondansetron (Zofran ODT) in Pregnancy: Safety Profile and Guidelines

Current Evidence-Based Guidance

Ondansetron (5-HT3 antagonist) is widely used for nausea/vomiting in pregnancy (NVP), including hyperemesis gravidarum.

First Trimester (Weeks 0–13)

  • Large cohort studies (Nordic, Medicaid) show no significant increase in major congenital malformations overall.
  • Slight absolute risk increase for cleft palate (~0.3% vs 0.1% baseline) in some studies; not consistently replicated.
  • ACOG: Consider after failed first-line (doxylamine/B6); not first-line.

Second/Third Trimester

  • Less data; theoretical concern for fetal serotonin receptor effects.
  • No clear evidence of cardiac defects, growth restriction, or preterm birth.
  • Use if benefits outweigh risks; lowest effective dose.

Practical Recommendations

  1. First-line: Lifestyle/dietary changes → Vitamin B6 (25 mg TID) ± Doxylamine (12.5 mg TID) [Diclegis/Bonjesta].
  2. Second-line: Ondansetron 4–8 mg PO/IV/ODT q8h PRN.
  3. Monitor for: QT prolongation (ECG if risk factors), constipation, headache, serotonin syndrome (with other serotonergic drugs).
  4. Reassess need each trimester.

Key Points

  • ODT formulation useful if swallowing difficult.
  • Not FDA-approved for NVP (off-label); extensive real-world use.
  • Discuss with OB provider; individualize based on severity, comorbidities, gestational age.

Babies & Teething - Related Articles